Holen Sie sich die Stockscreener-App
19.01
1.88%
0.35
Handel nachbörslich:
19.20
0.19
+1.00%
Schlusskurs vom Vortag:
$18.66
Offen:
$18.98
24-Stunden-Volumen:
2.65M
Relative Volume:
0.96
Marktkapitalisierung:
$14.15B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-18.87
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
+8.69%
1M Leistung:
+3.82%
6M Leistung:
-15.92%
1J Leistung:
+4.68%
1-Tages-Spanne:
$18.66
$19.51
1-Wochen-Bereich:
$17.29
$19.51
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.01 | 13.89B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Price-Driven Insight from (SMMT) for Rule-Based Strategy - Stock Traders Daily
Cantor Fitzgerald reaffirms overweight rating on Summit Therapeutics (SMMT) before key 2026 catalyst - MSN
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst - Finviz
Summit Therapeutics Earnings Notes - Trefis
15 Best Stocks Under $25 to Buy Now - Insider Monkey
Farther Finance Advisors LLC Makes New $1.14 Million Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Capricorn Fund Managers Ltd Takes $10.25 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Closing the Year With Gratitude and Shared Purpose – Summit Therapeutics - Oncodaily
Summit Therapeutics Inc. (SMMT) Stock Analysis: An 83.78% Potential Upside In Biotech - DirectorsTalk Interviews
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Summit Therapeutics Inc. stock a defensive play in 20252025 Price Momentum & Free Community Consensus Stock Picks - Улправда
How Summit Therapeutics Inc. stock compares to industry benchmarks2025 Big Picture & Long Hold Capital Preservation Plans - ulpravda.ru
Will Summit Therapeutics Inc. stock outperform Dow Jones indexPortfolio Return Report & AI Powered Buy and Sell Recommendations - ulpravda.ru
How Summit Therapeutics Inc. stock valuations compare to rivalsJuly 2025 Opening Moves & Community Verified Trade Alerts - DonanımHaber
Can Summit Therapeutics Inc. stock continue upward trendJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Gap Down: How Summit Therapeutics Inc. stock valuations compare to rivalsWeekly Market Summary & Low Risk Profit Maximizing Plans - DonanımHaber
Gains Recap: Will Summit Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Улправда
Barclays Upgrades Summit Therapeutics (SMMT) - Nasdaq
Barclays Upgrades SMMT, Raises Price Target to $18 | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Barclays to Equal Weight Rating - MarketBeat
Summit Therapeutics stock rating upgraded by Barclays on BLA timeline - Investing.com UK
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Trading Systems Reacting to (SMMT) Volatility - news.stocktradersdaily.com
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development - Yahoo Finance
Citi asserts buy rating on Summit Therapeutics Inc. (SMMT) on pipeline development - MSN
Has Summit Therapeutics Rally Left Enough Upside After 448.6% Surge and DCF Upswing? - Yahoo Finance
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
U.S. Markets Ended Tuesday Mixed As Galaxy Digital Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility - ts2.tech
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.4%Here's Why - MarketBeat
Norges Bank Invests $29.58 Million in Summit Therapeutics PLC $SMMT - MarketBeat
New York State Common Retirement Fund Buys 227,513 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Schroder Investment Management Group Sells 89,090 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
State Board of Administration of Florida Retirement System Boosts Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - Finviz
Why analysts upgrade Summit Therapeutics Inc. stockJuly 2025 Earnings & Weekly Chart Analysis and Guides - Newser
Summit Therapeutics Inc. (SMMT) Options Chain - Yahoo! Finance Canada
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - AOL.com
Summit Therapeutics (NASDAQ:SMMT) Trading 9.2% HigherShould You Buy? - MarketBeat
Can Summit Therapeutics Inc. stock maintain operating marginsWeekly Gains Report & AI Powered Market Trend Analysis - Newser
Don't Buy Summit Therapeutics Until This Big Thing Happen - Nasdaq
Widening Q3 Losses and Insider Buying Might Change The Case For Investing In Summit Therapeutics (SMMT) - Yahoo Finance
Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases - Yahoo Finance
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):